The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Argos Therapeutics, Inc. on January 23, 2019. The debtor has been authorized to sell substantially all its assets to SCM Lifescience Co., Ltd. and Genexine, Inc., the winning bidders at the auction, for a purchase price of $11.32 million in cash. At the auction held, SCM Lifescience Co., Ltd. and Genexine, Inc. emerged as the winning bidder by offering a purchase price of $11.32 million.